According to GlobalData’s company profile on Deciphera Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of February 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11918564B1) discloses a pharmaceutical composition designed for the oral delivery of a compound represented by Formula (I). The composition includes a solid dispersion containing an amorphous form of the compound, ensuring efficient delivery and absorption in the body.

Furthermore, the pharmaceutical composition may also include one or more pharmaceutically acceptable carriers along with the solid dispersion. This combination enhances the stability and bioavailability of the compound represented by Formula (I) when administered orally. Additionally, a specific embodiment of the composition includes 50 mg of the compound in its amorphous form within the solid dispersion, highlighting a precise dosage for effective delivery.

To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies